SOLICITATION NOTICE
66 -- Illumina MiSeq Reagent Kits
- Notice Date
- 7/19/2012
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120109-MD
- Archive Date
- 8/17/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Genetics Branch plans to procure on a sole source basis with Illumina, Inc. of 5200 Illumina Way San Diego, CA 92122 for the brand name Illumina Miseq Reagent Kits. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR 13.106-1(b)(1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The Genetics Branch of the Center for Cancer Research at the National Cancer Institute is engaged in the study of cancer genetics. Investigating genetics alteration and its effect on the development and biology of cancer is an integral function of the Genetics Branch. By using ultra-high throughput, next generation sequencing, and whole-genome high-resolution beadchip reagents, we are able to study DNA/promoter interactions, gene expressions, methylation status, single nucleotide polymorphism (SNP), and investigate genomic rearrangements and the Illumina Genome Analyzer or MiSeq at the resolution and informatics levels never before possible. The Illumina Genome Analyzer is a massively parallel next-generation sequencing by synthesis instrument, which has become a core technology for genome analysis and discovery in our laboratory as is related to the biology of cancer. High throughput sequencing is a highly competitive and rapidly evolving technology where the ability to generate every increasing amounts of sequencing data is key. The MiSeq system uses a specifically designed and packaged all-inclusive reagent cartridge system that is designed to deliver reagents necessary for the cluster generation, sequencing, and paired-end chemistry. These reagents and cluster kits are specifically formulated to be run on NIH's Illumina MiSeq Genome Analyzers, S/N 01876586 and S/N 01876609. The reagent content is proprietary, protected under patent rights, and is unavailable from sources other than the original manufacturer. Use of any other source reagents on these instruments would void support of the assays by Illumina. Illumina is the sole known source for MiSeq reagent kits. They are the manufacturer and distributor of both, the Miseq system and the specially designed reagent kits that are used with it. For these reasons, Illumina is the only source known to the NCI capable of fulfilling this requirement. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 02, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120109-MD on all correspondences
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120109-MD/listing.html)
- Record
- SN02809386-W 20120721/120720001144-1298239390cd090ab067b088eca408ea (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |